Abstract
The aim was to research the pharmacotherapy of psoriasis with antiphospholipid syndrome based on ABC/VEN analysis of antiviral drugs. The materials of the study were the clinical and pharmacological groups for pharmacotherapy of psoriasis on the background of antiphospholipid syndrome. Regulatory, documentary, marketing, pharmacoeconomic, ABC/VEN research methods were used. Studied the clinical and pharmacological groups of the most drugs INN for basic pharmacotherapy of psoriasis have diagnostic codes of ATC classification L "Antineoplastic and immunomodulatory agents" and code M "Agents affecting the musculoskeletal system". In the article, the results of share of different medical forms of drugs for pharmacotherapy of psoriasis with antiphospholipid syndrome were shown. Matrix of the consolidated ABC-VEN analysis of drugs for pharmacotherapy of psoriasis with antiphospholipid syndrome was developed during the research. Shown the relevance and necessity of the chosen research topic because of a review of the scientific literature on epidemiology and pharmacotherapy. Marketing research of medicines were determined by assortment, country of origin, dosage forms, and registration certificates. Estimated that in the A/E categories, drugs coincide and are in a niche with an affordable share (17.04%). In terms of priority for pharmacotherapy of psoriasis on the background of antiphospholipid syndrome, a matrix of the combined ABC/VEN analysis was developed. The results of the study provide an opportunity to make administrative and managerial decisions in determining the pharmacotherapy of psoriasis with antiphospholipid syndrome to improve the use pharmaceutical provision for patients with systemic autoimmune diseases.
Highlights
The growing incidence and social significance of psoriasis have been reflected in World Health Organization documents
Drug therapy for antiphospholipid syndrome in patients with systemic autoimmune diseases in the case of psoriasis included the use of antiviral drugs
At a later stage, marketing and pharmacoeconomic studies of drugs according to International Nonproprietary name (INN) Inosine pranobex by PBX code J05AX05 (Table 1) were conducted
Summary
The growing incidence and social significance of psoriasis have been reflected in World Health Organization documents. Non-infectious, painful, disfiguring and disabling disease that cannot be treated. In addition to the pain, itching, and bleeding caused by psoriasis, many patients around the world experience stigma and discrimination in society and at work. 42% of patients with psoriasis develop psoriatic arthritis, which causes pain, stiffness and swelling of the joints and can lead to irreversible disfigurement and disability. Often psoriasis causes damage to joints, internal organs, often accompanied by secondary microbial skin lesions and superinfection. Severe forms of psoriasis and psoriatic arthritis are associated with increased mortality. Psoriasis significantly reduces the quality of life of the patient. The negative impact on quality of life is comparable to that of coronary heart disease, diabetes, depression and oncology [1, 2]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
